Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
- Katz, D.A.
- Morris, J.D.
- Chu, M.P.
- David, K.A.
- Thieblemont, C.
- Morley, N.J.
- Khan, S.S.
- Viardot, A.
- Martín García-Sancho, A.
- Rodríguez-García, G.
- Bastos-Oreiro, M.
- Lee, S.T.
- Kormany, W.
- Chen, Y.
- Wong, H.L.
- Anderson, A.A.
- Katlinskaya, Y.
- Avilion, A.A.
- Dai, T.
- González-Barca, E.
ISSN: 1029-2403, 1042-8194
Argitalpen urtea: 2022
Alea: 63
Zenbakia: 9
Orrialdeak: 2063-2073
Mota: Artikulua